(Core A) The Administrative Core (Core A) will provide support and effort coordination for each of the projects in this P01, as well as the two scientific cores.
The aims of the Administrative Core are to ensure that the resources within the P01 are distributed equitably to the investigators and that all rules and regulations of the National Cancer Institute and the National Institutes of Health are followed. The Administrative Core will coordinate meetings of the investigators and their laboratories and facilitate communication between our investigators with the External Advisory Board. The finances of the P01 will be organized by Ms. Jenine Iannaccone, Grants Administrator in the Department of Radiation Oncology, who will meet monthly with the P01 Principle Investigator and quarterly with each Project and Core Leader. Ms. Andrea Rycroft, Administrative Coordinator, will coordinate travel arrangements for the members of the P01, as well as the advisors who will visit the University of Pennsylvania. She will also provide administrative support for each of the P01 investigators for efforts related to the Program. It is anticipated that through the combined efforts of the Core Director Ms. Rycroft and Ms. Iannaccone, the research operations and communications of the P01 will run with optimum efficiency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA165997-07
Application #
10017916
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2013-09-18
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Zhao, Bin; Bhattacharya, Sabyasachi; Yu, Qiujing et al. (2018) Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia. Leuk Lymphoma 59:171-177
Bu, Yiwen; Yoshida, Akihiro; Chitnis, Nilesh et al. (2018) A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nat Cell Biol 20:104-115
Nguyen, Hao G; Conn, Crystal S; Kye, Yae et al. (2018) Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med 10:
Hong, Feng; Liu, Bei; Wu, Bill X et al. (2017) CNPY2 is a key initiator of the PERK-CHOP pathway of the unfolded protein response. Nat Struct Mol Biol 24:834-839
Rozpedek, W; Nowak, A; Pytel, D et al. (2017) Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways. Curr Mol Med 17:118-132
Ortiz, Angélica; Fuchs, Serge Y (2017) Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine 89:4-11
Katlinski, Kanstantsin V; Gui, Jun; Katlinskaya, Yuliya V et al. (2017) Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell 31:194-207
Davar, Diwakar; Fuchs, Serge Y; Kirkwood, John M (2016) BRAF Inhibitors and IFN?: Plus, Minus, or Indeterminate? J Natl Cancer Inst 108:
Bu, Yiwen; Diehl, J Alan (2016) PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. J Cell Physiol 231:2088-96
Gui, Jun; Gober, Michael; Yang, Xiaoping et al. (2016) Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation. J Invest Dermatol 136:1990-2002

Showing the most recent 10 out of 28 publications